Patients' lobbies cheer ruling on anti-cancer drug Glivec, as affordability and access to life-saving drugs get a leg-up.
In his press conference on Wednesday, Trump targeted drug-makers and vowed to bring back production in the US.
The government regulates prices of all other medicines.
Industry fears tougher US stance on IP after President Donald Trump asserted that foreign countries must pay a fair share for drug development costs. Aneesh Phadnis reports.
Industry is gathering scientific data to approach the regulator, DCGI, for a review of the suspension order.
A notice issued by the Indian Health Ministry at the weekend said that a government-appointed committee of experts had found that the banned combinations were "likely to involve risk to human beings, whereas safer alternatives to the said drug are available."
The Indian Pharmaceutical Alliance has approached regulator for a dialogue to understand the concern raised by it
India had been engaged in a contentious battle with the US over the issue, especially in the pharmaceutical sector.
The National Pharmaceutical Pricing Authority will soon notify prices of as many as 150 packs of essential medicines in line with the new pharma pricing policy, according to official sources.
Dispute over IPR was a bone of contention in bilateral ties till a couple of months ago.
The category is expected to cross Rs 38,400 crore by 2020.
Roadblocks ahead as these medicines could face new clinical tests, more scrutiny
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances